Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Before starting any Alzheimer’s medication, families need to understand exactly what the drug can and cannot do, what side effects are realistic, and whether the person’s current disease stage actually matches when doctors recommend treatment. Too many families begin medications expecting them to stop the disease progression entirely, only to discover months later that the drug slows decline slightly while causing nausea, diarrhea, or other quality-of-life problems. The medications currently available—donepezil (Aricept), rivastigmine (Exelon), galantamine (Razadyne), and memantine (Namenda)—do not reverse cognitive loss or halt disease progression in the way that many people hope.
Instead, they may preserve cognitive function for several months to a year in some patients before decline resumes. The right time to ask these questions is before the prescription is written, when you can still make an informed choice with your doctor about whether the potential benefits justify the potential downsides for your family member. Starting a medication and then stopping it weeks later because of unexpected side effects puts unnecessary stress on a person who already has difficulty adapting to changes. Families should approach the medication conversation as a dialogue, not as acceptance of a recommendation that comes with no alternatives or tradeoffs to discuss.
Table of Contents
- What Specific Medication Is Being Recommended, and What Does It Actually Do?
- What Side Effects Could Occur, and How Will They Be Monitored?
- What Stage of Alzheimer’s Does My Family Member Actually Have?
- What Is the Full Cost, Including What Insurance Will and Won’t Cover?
- How Will We Know If the Medication Is Working, and What If It’s Not?
- Does My Family Member Have Other Medical Conditions That Contraindicate This Medication?
- What Happens if We Want to Stop the Medication Later?
What Specific Medication Is Being Recommended, and What Does It Actually Do?
Each Alzheimer’s medication works through different mechanisms and is typically prescribed based on disease stage. Donepezil is approved for mild to moderate disease and works by blocking the enzyme that breaks down acetylcholine, a neurotransmitter involved in memory and attention. Memantine works differently, blocking abnormal activity at glutamate receptors, and is used in moderate to severe disease. Some patients receive both drugs together. The critical question to ask your doctor is: “What is the expected outcome if my family member takes this medication?” Most doctors will say something like “it may slow cognitive decline” or “it might preserve memory function for a few months.” Very few will say the medication prevents disease progression or returns lost cognitive ability, because neither is true.
A realistic example: A 72-year-old woman with early-stage Alzheimer’s starts donepezil. Without the medication, her doctor estimates she would lose 3 points on the Mini-Cog cognitive test annually. With donepezil, she might lose 2 points per year instead. After two years, the medication’s effect often plateaus, and decline continues at the original rate. She has not recovered any lost memory, but the medication may have delayed noticeable change by several months. This does not happen in every patient—some see minimal benefit, and some see none—and studies show the effect varies widely depending on genetics, overall health, and how early the disease was caught.
What Side Effects Could Occur, and How Will They Be Monitored?
Gastrointestinal side effects are the most common problem with acetylcholinesterase inhibitors like donepezil. Nausea, vomiting, and diarrhea occur in 5–25% of patients, depending on the drug and dose. These effects can be severe enough to trigger dehydration, especially in older adults who already have difficulty drinking enough fluids or who take multiple medications. A family member with difficulty swallowing (common in later Alzheimer’s stages) faces additional risk because swallowing problems worsen with certain medications, and aspiration risk increases.
Memantine has a different side-effect profile—dizziness, headache, and confusion—but confusion is particularly tricky in an Alzheimer’s patient because it becomes difficult to distinguish between drug-related confusion and disease-related cognitive decline. Before starting medication, ask your doctor: “What side effects would tell me this medication is not working for us, and at what point would we stop it?” Some families are told “give it four to six weeks to adjust,” but if your family member is losing weight due to persistent nausea or becoming more confused, waiting four weeks is not always the right call. Establish a clear threshold beforehand—for example, weight loss greater than 5 pounds in a month, persistent vomiting, or worsening behavioral symptoms—that would prompt a conversation about discontinuing. Also ask whether your family member’s other medications interact with the Alzheimer’s drug; sedatives, certain blood pressure medications, and some pain relievers can interact in ways that amplify side effects.
What Stage of Alzheimer’s Does My Family Member Actually Have?
Disease stage matters enormously because medications are studied and approved for specific stages, and prescribing outside those stages is using medication off-label. Mild cognitive impairment (MCI) and early-stage Alzheimer’s are when acetylcholinesterase inhibitors have the most evidence behind them, but some neurologists also prescribe them off-label in moderate disease, where evidence is weaker. In advanced Alzheimer’s, when a person is bedbound and nonverbal, medication benefits become questionable because the cognitive function being preserved is so minimal that quality-of-life issues take precedence. Yet some patients in advanced disease still receive donepezil or memantine because prior doctors prescribed them and no one stopped them.
Ask your doctor: “Based on cognitive testing, brain imaging, and my family member’s functional abilities, what stage do you think they’re at, and is medication recommended at this stage?” If the doctor has not done recent cognitive testing—through the Mini-Cog, Montreal Cognitive Assessment, or another standardized test—ask for one before starting medication. This gives you a baseline to measure against and ensures the diagnosis and stage are accurate. Some families confuse normal aging memory complaints (“I forgot where I put my keys”) with true dementia. If your family member can still manage finances, take medications independently, or live alone safely, they may not have progressed to a stage where medication is standard of care.
What Is the Full Cost, Including What Insurance Will and Won’t Cover?
Medication costs vary widely. Brand-name donepezil (Aricept) can cost $150–$300 monthly without insurance, though the generic version is cheaper—typically $15–$50 monthly depending on the pharmacy and your insurance formulary. Memantine (Namenda) is also available as a generic, reducing costs substantially. However, some insurance plans cover one medication but not another, or require that a family member try the cheaper generic first before approving a brand name or combination therapy.
If your family member switches insurance or transitions to Medicare, formulary coverage may change, forcing a medication change mid-year. Before starting any medication, call your insurance company or ask your doctor’s office to verify coverage. Ask: “What is my out-of-pocket cost per month? If coverage changes, what are alternatives?” For families managing multiple medications, the cumulative cost adds up quickly. Some medications come with copay assistance programs or manufacturer discounts if you qualify based on income, so ask your doctor’s office whether the medication maker offers these programs. If cost is a barrier and your family member is on multiple Alzheimer’s drugs plus other medications, it is reasonable to ask whether all of them are still necessary and whether deprescribing (intentionally stopping medications that no longer provide benefit) might be a conversation worth having.
How Will We Know If the Medication Is Working, and What If It’s Not?
This is a question many families skip, yet it is essential. Medications are considered “working” based on clinical trial standards, not on whether your family member suddenly remembers faces or conversations. Working means delaying decline compared to no medication. But how do you measure that at home? Many families cannot tell the difference and assume that if their family member is still declining cognitively—which they will be—the medication has failed. In reality, decline may simply be slower than it would have been without the drug.
Ask your doctor: “Can we use a specific measurement—like the Mini-Cog score every three months or a functional activities checklist—to track whether this medication is helping?” Also ask: “If at our next appointment we’ve seen no benefit and my family member has experienced side effects, can we talk about stopping it?” Many families feel trapped once medication starts, as if stopping it represents giving up. It does not. Stopping an ineffective medication that causes suffering is good medical practice. Some people benefit enormously; many do not. There is no shame in concluding after two or three months that the tradeoff is not worthwhile for your family member.
Does My Family Member Have Other Medical Conditions That Contraindicate This Medication?
Heart rhythm problems, severe kidney disease, and active ulcers are just a few conditions that can make Alzheimer’s medications riskier or contraindicated outright. Acetylcholinesterase inhibitors can slow heart rate and cause fainting; memantine can worsen kidney function if your family member has advanced renal disease. Some medications used for Alzheimer’s interact dangerously with blood thinners, certain diabetes medications, or psychiatric drugs.
A family member on a pacemaker or with a history of syncope (fainting) faces particular risk from heart-rate-lowering effects. Before starting medication, ensure your doctor has a complete medication list and recent lab work showing kidney and liver function. Ask: “Given my family member’s heart history/kidney function/other medical issues, is this medication safe, or would an alternative be better?” Do not assume that a medication recommended by a neurologist has been reviewed for safety with the cardiologist, nephrologist, or primary care doctor who manages other conditions. Coordination between specialists is necessary but not automatic, and it is your job as a family member to flag any conditions or medications the specialist may not know about.
What Happens if We Want to Stop the Medication Later?
Some families start medication with the intention of “trying it for a few months,” but lack clarity on when or how to stop. Stopping abruptly can sometimes worsen symptoms temporarily—not because the medication was working wonderfully, but because the brain adapts to the drug’s presence. Some doctors recommend tapering down over weeks rather than stopping suddenly. Other doctors say the taper makes no difference with Alzheimer’s medications specifically.
The point is to clarify beforehand what stopping looks like. Ask your doctor: “If we decide this medication is not right for us, how would we stop it—all at once or gradually? How long should we expect any adjustment period?” Also: “If we stop it, can we restart it later if we change our minds?” Having these answers in advance means you are not making medical decisions in crisis mode if your family member develops severe side effects or if changing circumstances (like entering a nursing home) prompt a medication review. Some families regret not stopping medication earlier when their family member’s quality of life was being harmed by side effects. Knowing your exit plan removes some of that pressure from the decision and makes it easier to choose medication if you feel confident you can reassess later.
